Latest
-
Precision Cancer Medicines for Colon Cancer
Genomic testing identifies genetic targets that can be treated with precision cancer medicines avoiding chemotherapy
-
FDA Approves Enhertu for Two New Indications in HER2-Positive Early-Stage Breast Cancer
The targeted therapy T-DXd is now approved both before and after surgery for early-stage HER2-positive breast cancer, offering new options to improve outcomes for patients at high risk of recurrence, with studies showing 92% of patients with residual disease remained disease-free at three years.
Welcome to CancerConnect
CancerConnect is a unique resource that brings patients, caregivers, advocates and experts together – individuals benefit from a blend of expert-authored news and educational programming alongside a robust social network, providing insight into symptoms, diagnosis, and treatment and the support of other individuals being treated at some of the best cancer centers. CancerConnect offers users expert authored clinically-reviewed information and the perspective of their peers in a safe, objective space, helping to ensure they become empowered in their healthcare journey. Search the over 7000 articles on the management of cancer.
